Literature DB >> 18340431

Glucose lowers the threshold for human aortic vascular smooth muscle cell migration: inhibition by protein phosphatase-2A.

M Campbell1, P Anderson, E R Trimble.   

Abstract

AIMS/HYPOTHESIS: Atherosclerosis, which occurs prematurely in individuals with diabetes, incorporates vascular smooth muscle cell (VSMC) chemotaxis. Glucose, through protein kinase C-beta(II) signalling, increases chemotaxis to low concentrations of platelet-derived growth factor (PDGF)-BB. In VSMC, a biphasic response in PDGF-beta receptor (PDGF-betaR) level occurs as PDGF-BB concentrations increase. The purpose of this study was to determine whether increased concentrations of PDGF-BB and raised glucose level had a modulatory effect on the mitogen-activated protein kinase/extracellular-regulated protein kinase pathway, control of PDGF-betaR level and chemotaxis.
METHODS: Cultured aortic VSMC, exposed to normal glucose (NG) (5 mmol/l) or high glucose (HG) (25 mmol/l) in the presence of PDGF-BB, were assessed for migration (chemotaxis chamber) or else extracted and immunoblotted.
RESULTS: At concentrations of PDGF-BB <540 pmol/l, HG caused an increase in the level of PDGF-betaR in VSMC (immunoblotting) versus NG, an effect that was abrogated by inhibition of aldose reductase or protein kinase C-beta(II). At higher concentrations of PDGF-BB (>540 pmol/l) in HG, receptor level was reduced but in the presence of aldose reductase or protein kinase C-beta(II) inhibitors the receptor levels increased. It is known that phosphatases may be activated at high concentrations of growth factors. At high concentrations of PDGF-BB, the protein phosphatase (PP)2A inhibitor, endothall, caused an increase in PDGF-betaR levels and a loss of biphasicity in receptor levels in HG. At higher concentrations of PDGF-BB in HG, the chemoattractant effect of PDGF-BB was lost (chemotaxis chamber). Under these conditions inhibition of PP2A was associated with a restoration of chemotaxis to high concentrations of PDGF-BB. CONCLUSION/
INTERPRETATION: The biphasic response in PDGF-betaR level and in chemotaxis to PDGF-BB in HG is due to PP2A activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18340431     DOI: 10.1007/s00125-008-0962-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  39 in total

1.  High glucose attenuates insulin-induced mitogen-activated protein kinase phosphatase-1 (MKP-1) expression in vascular smooth muscle cells.

Authors:  N Takehara; J Kawabe; Y Aizawa; N Hasebe; K Kikuchi
Journal:  Biochim Biophys Acta       Date:  2000-07-21

2.  Epidermal growth factor and platelet-derived growth factor in blood in diabetes mellitus.

Authors:  A Lev-Ran; D L Hwang
Journal:  Acta Endocrinol (Copenh)       Date:  1990-09

Review 3.  Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle.

Authors:  A D Hughes; G F Clunn; J Refson; C Demoliou-Mason
Journal:  Gen Pharmacol       Date:  1996-10

4.  Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII.

Authors:  Malcolm Campbell; Elisabeth R Trimble
Journal:  Circ Res       Date:  2004-12-09       Impact factor: 17.367

5.  Internal mammary artery smooth muscle cells resist migration and possess high antioxidant capacity.

Authors:  Vaikom S Mahadevan; Malcolm Campbell; Pascal P McKeown; Ulvi Bayraktutan
Journal:  Cardiovasc Res       Date:  2006-06-27       Impact factor: 10.787

6.  The Src/PLC/PKC/MEK/ERK signaling pathway is involved in aortic smooth muscle cell proliferation induced by glycated LDL.

Authors:  Hyun-Mi Cho; Sung Hee Choi; Ki-Chul Hwang; Sue-Young Oh; Ho-Gyung Kim; Deok-Hyo Yoon; Myung-Ae Choi; Soyeon Lim; Heesang Song; Yangsoo Jang; Tae Woong Kim
Journal:  Mol Cells       Date:  2005-02-28       Impact factor: 5.034

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

8.  The effects of glucose-induced oxidative stress on growth and extracellular matrix gene expression of vascular smooth muscle cells.

Authors:  P C Sharpe; K K Yue; M A Catherwood; D McMaster; E R Trimble
Journal:  Diabetologia       Date:  1998-10       Impact factor: 10.122

Review 9.  Osteogenic regulation of vascular calcification: an early perspective.

Authors:  Radhika Vattikuti; Dwight A Towler
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-05       Impact factor: 4.310

10.  Oxidized low density lipoprotein-mediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis.

Authors:  V Natarajan; W M Scribner; C M Hart; S Parthasarathy
Journal:  J Lipid Res       Date:  1995-09       Impact factor: 5.922

View more
  3 in total

1.  Ca2+/calmodulin-stimulated PDE1 regulates the beta-catenin/TCF signaling through PP2A B56 gamma subunit in proliferating vascular smooth muscle cells.

Authors:  Kye-Im Jeon; Hirofumi Jono; Clint L Miller; Yujun Cai; Soyeon Lim; Xuan Liu; Pingjin Gao; Jun-Ichi Abe; Jian-Dong Li; Chen Yan
Journal:  FEBS J       Date:  2010-11-16       Impact factor: 5.542

2.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

3.  Protein Phosphatase 2A Deficiency in Macrophages Increases Foam Cell Formation and Accelerates Atherosclerotic Lesion Development.

Authors:  Rui Li; Chao Zhang; Fei Xie; Xianming Zhou; Xingjian Hu; Jiawei Shi; Xinling Du; Zhiyong Lin; Nianguo Dong
Journal:  Front Cardiovasc Med       Date:  2022-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.